N/A
Completed N=53
Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT00549445 ↗
Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Aug 2017
Primary outcomePrimary: Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin. — 2.27; 5.15 ng/mL — p=0.045
Summary
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Azithromycin, an antibiotic, may be beneficial at reducing the symptoms and severity of the disease. This study will analyze previously collected study data to evaluate the anti-inflammatory properties of azithromycin and determine how azithromycin affects the frequency and severity of COPD exacerbations.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Levels of PGP From Sputum Samples of COPD Patients Being Treated With Azithromycin. |
2.27; 5.15 | 0.045 sig |
Eligibility Criteria
Inclusion Criteria
- Participating in the COPD Network Macrolide study
- Clinical diagnosis of at least moderate COPD
- Cigarette consumption of 10 pack years or more
Exclusion Criteria
- Diagnosis of asthma
- Predicted life expectancy of less than 3 years
- History of hypersensitivity to macrolide antibiotics
- Long-term kidney insufficiency
- Long-term liver insufficiency
- Prolonged QT interval
- Use of medications that may prolong the QT interval
Data sourced from ClinicalTrials.gov (NCT00549445). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.